Total Payments
$223,363
2024 Payments
$43,493
Companies
25
Transactions
285
Medicare Patients
656
Medicare Billing
$131,832
Payment Breakdown by Category
Consulting$93,491 (41.9%)
Travel$52,257 (23.4%)
Other$48,489 (21.7%)
Research$21,542 (9.6%)
Food & Beverage$7,475 (3.3%)
Education$109.08 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $93,491 | 34 | 41.9% |
| Travel and Lodging | $52,257 | 67 | 23.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,460 | 34 | 20.4% |
| Unspecified | $21,542 | 32 | 9.6% |
| Food and Beverage | $7,475 | 114 | 3.3% |
| Honoraria | $2,800 | 1 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $228.66 | 1 | 0.1% |
| Education | $109.08 | 2 | 0.0% |
Payments by Type
General
$201,821
253 transactions
Research
$21,542
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $88,160 | 74 | $0 (2024) |
| Kite Pharma, Inc. | $43,968 | 51 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $30,245 | 44 | $0 (2024) |
| Genentech, Inc. | $13,580 | 18 | $0 (2023) |
| Gilead Sciences, Inc. | $12,919 | 19 | $0 (2018) |
| Celgene Corporation | $9,183 | 10 | $0 (2021) |
| Genentech USA, Inc. | $7,439 | 14 | $0 (2024) |
| ADC Therapeutics America, Inc. | $4,511 | 7 | $0 (2024) |
| AstraZeneca UK Limited | $3,596 | 3 | $0 (2024) |
| Janssen Global Services, LLC | $3,108 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,493 | 46 | F. Hoffmann-La Roche AG ($37,855) |
| 2023 | $17,999 | 29 | F. Hoffmann-La Roche AG ($6,348) |
| 2022 | $20,003 | 23 | Genentech, Inc. ($5,088) |
| 2021 | $8,888 | 9 | Genentech, Inc. ($3,850) |
| 2020 | $23,040 | 9 | F. Hoffmann-La Roche AG ($22,233) |
| 2019 | $36,107 | 53 | AstraZeneca Pharmaceuticals LP ($16,120) |
| 2018 | $54,199 | 98 | Kite Pharma, Inc. ($25,373) |
| 2017 | $19,634 | 18 | F. Hoffmann-La Roche AG ($10,364) |
All Payment Transactions
285 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,451.03 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,357.77 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,079.32 | Research |
| Study: Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $953.70 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $831.45 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $764.68 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $664.77 | Research |
| Study: MorningSun | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $576.13 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $498.26 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $385.46 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $381.08 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $381.00 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.02 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.02 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $268.78 | Research |
| Study: Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | ||||||
| 12/09/2024 | Incyte Corporation | MONJUVI (Drug), NIKTIMVO | Food and Beverage | Cash or cash equivalent | $44.33 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.01 | General |
| 12/05/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $129.54 | General |
| Category: BioOncology | ||||||
| 11/11/2024 | Genentech USA, Inc. | Lunsumio (Biological), Columvi, Polivy | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,000.20 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $263.00 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $136.47 | Research |
| Study: Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | ||||||
| 08/17/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $48.52 | General |
| Category: Oncology | ||||||
| 08/17/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $35.79 | General |
| Category: Oncology | ||||||
| 07/15/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $6.90 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | F. Hoffmann-La Roche AG | $9,237 | 13 |
| Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial | F. Hoffmann-La Roche AG | $3,011 | 1 |
| MorningSun | F. Hoffmann-La Roche AG | $2,944 | 3 |
| Ph1b 2 TDB Pola dose escalation in r r NHL Ph1b followed by expansion in r r DLBCL and r r FL Ph2 | F. Hoffmann-La Roche AG | $2,059 | 6 |
| Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL | F. Hoffmann-La Roche AG | $1,419 | 3 |
| Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-cell Lymphoma Using Real-World Data | F. Hoffmann-La Roche AG | $1,348 | 2 |
| Glofitamab Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated Large B-Cell Lymphoma Defined as High Risk by Circulating Tumor DNA: Preliminary Safety and Efficacy Results | F. Hoffmann-La Roche AG | $662.58 | 1 |
| A PHASE IB, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE OR RO7082859 IN COMBINATION WITH LENALIDOMIDE OR RO7082859 IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA | F. Hoffmann-La Roche AG | $361.25 | 1 |
| Glofitamab (Glofit) Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients (Pts) with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined as High Risk by Circulating Tumor DNA (ctDNA): Preliminary Safety and Efficacy Results | F. Hoffmann-La Roche AG | $332.81 | 1 |
| an Open-Label, Multicenter, Phase IIB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | F. Hoffmann-La Roche AG | $165.42 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 186 | 413 | $135,367 | $37,475 |
| 2022 | 4 | 149 | 401 | $109,949 | $34,905 |
| 2021 | 5 | 170 | 579 | $119,341 | $37,449 |
| 2020 | 3 | 151 | 493 | $85,932 | $22,004 |
Total Patients
656
Total Services
1,886
Medicare Billing
$131,832
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 50 | 106 | $40,280 | $12,508 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 153 | $39,168 | $12,062 | 30.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 93 | $40,378 | $9,277 | 23.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 44 | $12,702 | $2,786 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 16 | 17 | $2,839 | $841.39 | 29.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 81 | 255 | $65,280 | $20,677 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 69 | $26,220 | $8,387 | 32.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 46 | $12,466 | $3,982 | 31.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 31 | $5,983 | $1,861 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 73 | 271 | $69,376 | $22,877 | 33.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 32 | 196 | $24,304 | $6,425 | 26.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 20 | 29 | $11,020 | $3,626 | 32.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 53 | $8,851 | $2,658 | 30.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 30 | $5,790 | $1,862 | 32.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 61 | 154 | $39,424 | $10,190 | 25.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 44 | 235 | $29,140 | $7,629 | 26.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 46 | 104 | $17,368 | $4,184 | 24.1% |
About Lihua Budde, MD, PHD
Lihua Budde, MD, PHD is a Hematology & Oncology healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124030028.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lihua Budde, MD, PHD has received a total of $223,363 in payments from pharmaceutical and medical device companies, with $43,493 received in 2024. These payments were reported across 285 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($93,491).
As a Medicare-enrolled provider, Budde has provided services to 656 Medicare beneficiaries, totaling 1,886 services with total Medicare billing of $131,832. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Duarte, CA
- Active Since 08/12/2006
- Last Updated 11/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1124030028
Products in Payments
- Yescarta (Drug) $33,492
- CALQUENCE (Drug) $28,005
- VENCLEXTA (Biological) $27,562
- Non-Covered Product (Drug) $15,639
- Tecartus (Drug) $6,661
- Zydelig (Drug) $6,522
- Rituxan (Biological) $4,514
- Columvi (Biological) $2,575
- Lunsumio (Biological) $2,410
- BRUKINSA (Drug) $2,067
- TECENTRIQ (Biological) $1,776
- KYMRIAH (Biological) $824.05
- Epkinly (Drug) $157.67
- EPKINLY (Drug) $149.49
- GAZYVA (Biological) $132.28
- LYNPARZA (Drug) $118.19
- ONCASPAR (Biological) $110.84
- Kyprolis (Biological) $92.79
- DARZALEX (Biological) $91.18
- Revlimid (Drug) $90.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Duarte
Dr. Christine Lovly, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $302,848
Hematology & Oncology $302,848
Robert Figlin, Md, MD
Hematology & Oncology — Payments: $234,191
Hematology & Oncology $234,191
Dr. Leslie Popplewell, M.d, M.D
Hematology & Oncology — Payments: $206,204
Hematology & Oncology $206,204
Mrs. Tanya Dorff, M.d, M.D
Hematology & Oncology — Payments: $198,135
Hematology & Oncology $198,135
Dr. Michael Rosenzweig, M.d, M.D
Hematology & Oncology — Payments: $136,718
Hematology & Oncology $136,718
Dr. Steven Rosen, M.d, M.D
Hematology & Oncology — Payments: $111,332
Hematology & Oncology $111,332